Bringing the fundamentals into focus…
Back to Abrdn Life Sciences Investors
How Abrdn Life Sciences Investors stacks up
HQL · against 122 other Financial Services companies of similar size
Growth
27/ 100
Below the middle of the pack.
Ranked #78 of 123 · scores higher than 36% of peers
Bars: peers in each 10-point band of the growth score15 peers with a growth score of 20–29, including HQL · Click a bar to see the companies
Why growth scores 27?
Weighted metrics compared with all Financial Services companies.Mainly because of its revenue growth and earnings per share growth, which are weaker than most Financial Services peers.
- slower revenue growth over the last year: weaker than 70% of peers. Revenue growth: -0.3% vs peer median 7.4%
- slower growth in earnings per share: weaker than 68% of peers. Earnings per share growth: -8.2% vs peer median 10.0%
- 3-year revenue growth is not reported, so it is left out of the score.
Metric by metric
Position: dot = HQL, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | HQL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 138 reported | -0.3% | 4.0% | 42% | 33% | |
| Earnings per share growthHigher is better · 92 reported | -8.2% | -2.3% | 44% | 33% | |
| 3-year revenue growthHigher is better · 106 reported | Not reported | 6.8% | — | — | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around HQLScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score